ATLANTA, Dec. 6 /PRNewswire/ -- Data from 11 PROCRIT(R) (Epoetin alfa)
studies will be presented at the American Society of Hematology (ASH) 49th
Annual Meeting and Exposition December 8 - 11, 2007.
The data will provide important insights including:
-- the potential impact on the nation's blood supply of limiting the use
of erythropoiesis-stimulating agents (ESAs) for the treatment of
chemotherapy-induced anemia (CIA);
-- the use of PROCRIT in extended dosing regimens;
-- the use of PROCRIT for treatment of transfusion-dependent anemia in
patients with myelodysplastic syndromes (MDS);
-- PROCRIT and real-world practice patterns;
-- PROCRIT in managed care settings; and
-- observational data from the Dosing Outcomes Study of Erythropoiesis-
Stimulating Therapies (DOSE) Registry.
In some cases, the data are from investigational studies and do not reflect current U.S. Food and Drug Administration (FDA)-approved PROCRIT indications or recommended dosage and administration. Please note that all information presented at ASH is embargoed for media release until the data are made available to the public on the ASH Web site.
Data on the Potential Impact on Blood Supply of Limiting ESA Use for
-- Poster: Impact of Limiting Erythropoiesis-Stimulating Agent Use for
Chemotherapy-Induced Anemia on the United States Blood Supply
Francis Vekeman, M.A., Groupe d'analyse, Ltee, Montreal, Quebec, Canada
Presentation: Monday, December 10, 2007; 5:00pm - 7:00pm; Hall B3 and
B4 in the Georgia World Congress Center (Poster Board Number 115,
Publication Number 2896)
A modeling simulation was employed to estimate the impact of limiting
the use of ESAs for CIA on the U.S. blood supply. The model used a
top-down approach to compare the number of red blood cell units
|SOURCE Ortho Biotech|
Copyright©2007 PR Newswire.
All rights reserved